Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Warner Chilcott | WCRX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | - |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| Top Posts |
|---|
Posted at 20/9/2004 09:52 by samuri Hadn't realised people not seen this a.m's news.Craigavon, Northern Ireland/Rockaway, New Jersey, USA - 20 September 2004: Warner Chilcott PLC ('Warner Chilcott') (LSE: WCRX, Nasdaq: WCRX). The board of Directors has noted the recent speculation in the media regarding the possibility of an offer for the Company. The board can confirm that they have received an approach from a consortium of private equity houses which may or may not lead to an offer, at an indicative cash price of 800p per share, being made for the entire issued share capital of Warner Chilcott. The board, other than Roger Boissonneault, the Chief Executive Officer, who in view of the nature of the approach is not currently participating in these deliberations, is considering the appropriate response to this approach. The board wish to make clear that the approach they have received is preliminary in nature and is subject to, inter alia, various pre-conditions including financing and due diligence. There can be no certainty that an offer will actually be made. Furthermore, there can be no certainty as to the level of any offer. A further announcement will be made in due course, if appropriate. |
Posted at 11/8/2004 08:14 by samuri Merrills (Co's broker & advisor) have reiterated their buy with a prospective eps of 60p. This gives a pe of 9.6 at 577p, growth forecast at 15% giving a peg of 0.64. Sector av pe >15 therefore I believe that WCRX is undervalued and has room for upside move.Also bought back 1.5m shares yesterday. |
Posted at 30/7/2004 16:21 by willyk Warner Chilcott PLC30 July 2004 WARNER CHILCOTT PLC WARNER CHILCOTT RECEIVES POSITIVE COURT DECISION ON SARAFEM(R) LITIGATION Craigavon, Northern Ireland, UK/Rockaway, New Jersey, US, July 30, 2004 - Warner Chilcott PLC ('Warner Chilcott') (LSE: WCRX.L, Nasdaq: WCRX), today announced that it has received a decision from the United States District Court for the Southern District of Indiana concerning its patent litigation dispute with Teva Pharmaceuticals (Teva). The case was initiated in response to an abbreviated new drug application (ANDA) filed by Teva to market a generic version of Sarafem(R), the US sales and marketing rights of which were acquired from Eli Lilly & Co. (Lilly) by Warner Chilcott in January 2003. Sarafem is indicated for the treatment of Pre-Menstrual Dysphonic Disorder (PMDD). Under the ruling, Judge Barker has found in favour of Lilly and Warner Chilcott, and upheld the validity of the Sarafem(R) patent. As a result, injunctive relief is available to Warner Chilcott until the expiration of the patent in May 2008. Commenting on the court's decision, Roger Boissonneault, CEO of Warner Chilcott said, 'We are extremely pleased to hear that the court has found in our favour in this case. Sarafem(R) is, and will continue to be, an important product for us and following this decision, we will continue to move forward with our plans to develop the PMDD market and introduce new products under the Sarafem(R) brand ' |
Posted at 20/7/2004 08:31 by samuri Very aggravating I agree, particularly after such good figures for March. Maybe there is a fear that the momentum cannot be sustained. The only answers I can suggest are:1. Pfizers warning (and another US pharma I think) last week could impact WCRX, as bulk of revenues now generated in US. 2. JP Morgan have reiterated an overweight stance on AstraZ ahead of their results with a target price of £32. This may have prompted investors to switch from WC to AZ. 3. Market generally continues to fall. From a charting point of view the RSI is now less than 19 indicating a very oversold position. Results for June quarter should be out mid Aug and one hopes for continued good performance with no surprises. |
Posted at 20/7/2004 08:25 by matthu I look forward to their reply. Meanwhile, WCRX have been tipped by Goodbody Stockbrokers:Goodbody Stockbrokers is among the growing list of fans behind (Elan). Recently tipped to hit $45 Goodbody's Ian Hunter is a bit more phlegmatic about the stock, though positive it will go above $31. Mr Hunter says that the group is beginning to return to prosperity having eliminated the high financial risks that caused its share price to plunge in 2002. ... In his assessment of the other publicly-quoted pharmaceutical stocks Mr Hunter tips Warner Chilcott as the other share buy. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
